Japan

Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
Alnylam Submits NDA in Japan for Onpattro for Hereditary ATTR Amyloidosis
CP Wire
Alnylam
Patisiran
Onpattro
Japan
hATTR amyloidosis
Flag link:
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
Canada Approves Cabometyx for Adults with Previously Treated Advanced Renal Cell Carcinoma
CP Wire
Exelixis
Cabometyx
Takeda
Canada
Japan
Ipsen
renal cell carcinoma
Flag link:
AstraZeneca gets further approval for Tagrisso in Japan
AstraZeneca gets further approval for Tagrisso in Japan
Pharmaforum
AstraZeneca
Japan
Tagrisso
non-small cell lung cancer
Flag link:
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Shire, Shionogi File NDA for Intuniv for Adults in Japan
Yahoo/Zacks.com
Shire
Shionogi
ADHD
Japan
Intuniv
Flag link:
Pharma reps get more respect from doctors in Japan. What's the takeaway for U.S. reps?
Pharma reps get more respect from doctors in Japan. What's the takeaway for U.S. reps?
Fierce Pharma
drug reps
Japan
Flag link:
Pharma reps and websites carry clout with physicians in Japan
Pharma reps and websites carry clout with physicians in Japan
Decision Resources Group
Japan
pharma reps
Decision Resources Group
Flag link:
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories
CP Wire
AB928
Arcus Biosciences
Taiho Pharmaceutical
oncology
Asia
Japan
Flag link:
Takeda posts ‘for-sale’ sign on company’s ancestral home in Osaka in effort to fund Shire buyout
Takeda posts ‘for-sale’ sign on company’s ancestral home in Osaka in effort to fund Shire buyout
Endpoints
Takeda
Shire
M&A
Japan
Flag link:
AstraZeneca wins speedy approvals for cancer drugs in Japan
AstraZeneca wins speedy approvals for cancer drugs in Japan
Yahoo/Reuters
AstraZeneca
Japan
Imfinzi
Lynparza
Flag link:
What to Expect for AstraZeneca in Fiscal 2018
What to Expect for AstraZeneca in Fiscal 2018
Market Realist
AstraZeneca
guidance
generics
Crestor
Japan
Europe
Flag link:
Astellas to pay Aquinox $25M upfront for regional rights to phase 3 inflammatory pain drug
Astellas to pay Aquinox $25M upfront for regional rights to phase 3 inflammatory pain drug
Fierce Biotech
Astellas
Aquinox Pharmaceuticals
SHIP1 activator
Japan
Asia
rosiptor
Flag link:
Myriad’s breast cancer diagnostic wins approval in Japan
Myriad’s breast cancer diagnostic wins approval in Japan
Drug Delivery Business News
Myriad Genetics
diagnostics
breast cancer
Japan
Bracanalysis Diagnostic System
Lynparza
Flag link:
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Drug Delivery Business News
Japan
Novo Nordisk
diabetes
type 2 diabetes
Ozempic
Flag link:
Reimbursement Trends for Medical Devices in Japan
Reimbursement Trends for Medical Devices in Japan
Medical Devices and Diagnostics Industry
devices
Japan
reimbursement
Flag link:
Shionogi’s flu drug wins green light in Japan, but U.S. approval not likely until 2019
Shionogi’s flu drug wins green light in Japan, but U.S. approval not likely until 2019
Fierce Pharma
Japan
Shionogi
Flu
influenza
Xofluza
Flag link:
Shionogi, Roche get their first approval for the next big thing in fighting the flu
Shionogi, Roche get their first approval for the next big thing in fighting the flu
Endpoints
Shionogi
Roche
Flu
influenza
Xofluza
Japan
Tamiflu
Flag link:
Why Thailand is an Untapped Medtech Opportunity
Why Thailand is an Untapped Medtech Opportunity
Medical Devices and Diagnostics Industry
devices
Thailand
Japan
medical tourism
Flag link:
Drugmakers take to Japan: 3 new drug approvals won by AstraZeneca, Merck, and EA Pharma
Drugmakers take to Japan: 3 new drug approvals won by AstraZeneca, Merck, and EA Pharma
Endpoints
AstraZeneca
Lynparza
Merck
ovarian cancer
asthma
Japan
Fasenra
EA Pharma
elobixibat
Flag link:
Cancer Space Update: New Regulatory Status for 3 Major Drugs
Cancer Space Update: New Regulatory Status for 3 Major Drugs
Yahoo/Zacks.com
cancer
Merck
Japan
Keytruda
Seattle Genetics
Adcetris
Novartis
Kisqali
Flag link:
Bayer AG taps PeptiDream in billion-dollar deal
Bayer AG taps PeptiDream in billion-dollar deal
Endpoints
Bayer
R&D
Japan
PeptiDream
Flag link:

Pages